The Neonatal Kidney Collaborative (NKC) is dedicated to improving outcomes in neonates at risk for acute kidney injury. Spearheaded by Dr. David Askenazi, the group has developed a robust infrastructure to support collaboration among an international network of neonatologists, pediatric nephrologists, obstetricians and pediatricians. The NKC is currently engaged in the Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates (AWAKEN), a retrospective study that aims to determine if the AKI clinical practice guidelines (KDIGO) adapted to neonates can predict risk factors and outcomes such as mortality, length of stay, and discharge serum creatinine (SCr). Dr. Askenazi also works closely with Dr. Namasivayam Ambalavanan, MD, Director of the Translational Research in Normal & Disordered Development (TReNDD) Program, a collaborative group of investigators applying state of the art biological approaches to understanding human disorders of organogenesis. The CCTS Hub is the national coordinating center for the Neurofibromatosis (NF) Clinical Trials Consortium, with leadership from Dr. Bruce Korf. The NF Program is internationally recognized for its contributions to outstanding clinical care, research, and education related to all forms of neurofibromatosis (NF1, NF2, and schwannomatosis). This group recently characterized the role of LZTR1 mutations in the predisposition to multiple schwannomas, providing new insights for anti-tumor therapeutic approaches.

NKCV2